DOP2017000025A - Composiciones y métodos de uso para tratar trastornos metabólicos - Google Patents
Composiciones y métodos de uso para tratar trastornos metabólicosInfo
- Publication number
- DOP2017000025A DOP2017000025A DO2017000025A DO2017000025A DOP2017000025A DO P2017000025 A DOP2017000025 A DO P2017000025A DO 2017000025 A DO2017000025 A DO 2017000025A DO 2017000025 A DO2017000025 A DO 2017000025A DO P2017000025 A DOP2017000025 A DO P2017000025A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- compositions
- metabolic disorders
- treat metabolic
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan métodos para tratar individuos con un trastorno del metabolismo de la glucosa y/o un trastorno del peso corporal, y composiciones asociadas con estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031063P | 2014-07-30 | 2014-07-30 | |
US201562195908P | 2015-07-23 | 2015-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2017000025A true DOP2017000025A (es) | 2017-05-15 |
Family
ID=55179329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2017000025A DOP2017000025A (es) | 2014-07-30 | 2017-01-25 | Composiciones y métodos de uso para tratar trastornos metabólicos |
Country Status (29)
Country | Link |
---|---|
US (3) | US9834586B2 (es) |
EP (1) | EP3174894B1 (es) |
JP (1) | JP6704358B2 (es) |
KR (1) | KR20170065026A (es) |
CN (1) | CN106573966B (es) |
AP (1) | AP2016009663A0 (es) |
AU (1) | AU2015296640B2 (es) |
BR (1) | BR112017001789A2 (es) |
CA (1) | CA2953827A1 (es) |
CL (1) | CL2017000201A1 (es) |
CO (1) | CO2017000614A2 (es) |
CR (1) | CR20170027A (es) |
DO (1) | DOP2017000025A (es) |
EA (1) | EA035581B1 (es) |
EC (1) | ECSP17005276A (es) |
ES (1) | ES2883158T3 (es) |
IL (1) | IL249793B (es) |
MD (1) | MD20170020A2 (es) |
MX (1) | MX370115B (es) |
MY (1) | MY192917A (es) |
PE (1) | PE20170771A1 (es) |
PH (1) | PH12017500153A1 (es) |
SG (2) | SG10201802098UA (es) |
SV (1) | SV2017005367A (es) |
TN (1) | TN2016000578A1 (es) |
TW (1) | TWI710570B (es) |
UA (1) | UA123432C2 (es) |
WO (1) | WO2016018931A1 (es) |
ZA (1) | ZA201700311B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2014212640B2 (en) | 2013-01-30 | 2017-10-19 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
WO2015117024A1 (en) | 2014-01-31 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Novel therapeutics for the treatment of glaucoma |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
EP3174894B1 (en) | 2014-07-30 | 2021-06-23 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EP3212226B1 (en) * | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US10174119B2 (en) | 2016-03-31 | 2019-01-08 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
WO2018193033A1 (en) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
US11260108B2 (en) | 2017-09-10 | 2022-03-01 | Novo Nordisk A/S | MIC-1 and GLP-1 for use in the treatment of obesity |
JP2021511785A (ja) | 2018-01-19 | 2021-05-13 | ペプジーン インコーポレーテッドPepgene Inc. | 組換えポリペプチド生産用n末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法 |
TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
CN112543869A (zh) | 2018-08-10 | 2021-03-23 | 诺华股份有限公司 | Gfral细胞外结构域和使用方法 |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
US20230210950A1 (en) | 2019-10-04 | 2023-07-06 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
US20230002460A1 (en) * | 2019-11-26 | 2023-01-05 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
KR20210074224A (ko) * | 2019-12-11 | 2021-06-21 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역 및 gdf15를 포함하는 융합 폴리펩타이드 |
AU2020403144A1 (en) * | 2019-12-12 | 2022-07-14 | Mayo Foundation For Medical Education And Research | Controlled-delivery cromakalim prodrugs |
EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing Ql Biopharmaceutical Co Ltd | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | TGF−βスーパーファミリー蛋白質をコードするヒト新規cDNA |
JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
WO1996018730A1 (en) | 1994-12-15 | 1996-06-20 | Human Genome Sciences, Inc. | Prostatic growth factor |
US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
NZ310370A (en) | 1995-06-22 | 2001-04-27 | St | A TGF-beta like cytokine designated pCL13 |
US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
NZ334592A (en) | 1996-09-11 | 2000-10-27 | Ortho Mcneil Pharm Inc | Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer |
WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
EP1100822A1 (en) | 1998-07-23 | 2001-05-23 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
WO2000070051A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
CA2404163C (en) * | 2000-03-22 | 2009-09-29 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines |
AU2001250182B2 (en) | 2000-04-20 | 2006-06-08 | St Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
EP1354042A2 (en) | 2000-12-29 | 2003-10-22 | Curagen Corporation | Proteins and nucleic acids encoding same |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
WO2002072608A2 (en) | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
EA010435B1 (ru) | 2001-05-11 | 2008-08-29 | Амген, Инк. | Связывающиеся с tall-1 молекулы и их применение |
GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
CA2504508A1 (en) | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US8192735B2 (en) | 2004-04-13 | 2012-06-05 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
RU2401842C2 (ru) | 2004-10-08 | 2010-10-20 | Домантис Лимитед | Антагонисты и способы их применения |
SI1844337T1 (sl) | 2005-01-24 | 2013-11-29 | Pepscan Systems B.V. | Povezovalne spojine, imunogene spojine in peptidomimetiki |
JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
EP2650305B1 (en) | 2006-03-24 | 2024-05-08 | Bioverativ Therapeutics Inc. | PC5 as a factor IX propeptide processing enzyme |
US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
EP2377876A1 (en) | 2006-06-02 | 2011-10-19 | Wyeth LLC | Use of proteins and peptides of the TGF-BETA superfamily for purification and therapeutic methods |
US20100322945A1 (en) | 2006-07-26 | 2010-12-23 | Peter Timmerman | Immunogenic compounds and protein mimics |
CN106018820B (zh) | 2006-08-04 | 2018-04-27 | 汉诺威医学院 | 根据gdf-15评价心脏介入风险的工具与方法 |
CA2685148C (en) | 2007-04-25 | 2014-09-09 | Stem Cells Spin Sp.Z.O.O. | New stem cell lines, their application and culture methods |
BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
CN101765608B (zh) | 2007-07-31 | 2015-03-11 | 阿菲博迪公司 | 新白蛋白结合组合物、方法及应用 |
JP2010536717A (ja) | 2007-08-16 | 2010-12-02 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン(mic−1)活性を調節するための作用物質及び方法 |
CN101896192A (zh) | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
EP2208072B1 (en) | 2007-10-22 | 2015-07-01 | St Vincent's Hospital Sydney Limited | Methods of prognosis |
JP2011501958A (ja) * | 2007-10-29 | 2011-01-20 | バージニア テック インテレクチュアル プロパティーズ インコーポレーテッド | ブタDC−SIGN、ICAM−3およびLSECtinならびにそれらの使用 |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
JP2011509403A (ja) | 2008-01-08 | 2011-03-24 | エフ.ホフマン−ラ ロシュ アーゲー | Gdf−15に基づいて救急室を受診する患者のリスクを評価するための手段及び方法 |
US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
MX2010010776A (es) * | 2008-03-31 | 2010-10-26 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ.ホフマン−ラ ロシュ アーゲー | 1型糖尿病におけるバイオマーカーとしてのgdf−15 |
EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
US9012218B2 (en) | 2008-10-31 | 2015-04-21 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
ES2434996T3 (es) | 2008-10-31 | 2013-12-18 | St Vincent's Hospital Sydney Limited | Métodos de pronóstico en enfermedad renal crónica |
EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
US20100204123A1 (en) | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease |
GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Tgf-베타 슈퍼패밀리의 설계자 리간드 |
TWI560197B (en) | 2009-05-05 | 2016-12-01 | Amgen Inc | Fgf21 mutants and uses thereof |
MX2011013455A (es) | 2009-07-08 | 2012-02-13 | Amgen Inc | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. |
WO2011008956A2 (en) | 2009-07-15 | 2011-01-20 | Zirus, Inc. | Mammalian genes involved in infection |
WO2011050407A1 (en) | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Methods of diagnosing and prognosing colonic polyps |
AU2010314981B2 (en) | 2009-11-05 | 2015-07-02 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
CN105044349B (zh) | 2010-08-26 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
CN103492562B (zh) * | 2011-02-03 | 2017-04-05 | 佐马技术有限公司 | 用于增强细菌中功能蛋白表达的方法和材料 |
JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
DK2697257T3 (en) | 2011-04-13 | 2017-01-30 | Bristol Myers Squibb Co | FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS |
DK2728002T3 (da) | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
EA038645B1 (ru) | 2012-12-21 | 2021-09-28 | Авео Фармасьютикалз, Инк. | Антитела к gdf15 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
AU2014212640B2 (en) | 2013-01-30 | 2017-10-19 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
JP6456356B2 (ja) | 2013-03-15 | 2019-01-23 | ジェネンテック, インコーポレイテッド | IL−22ポリペプチド及びIL−22Fc融合タンパク質並びに使用方法 |
CN203123206U (zh) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
US20160193295A1 (en) | 2013-07-31 | 2016-07-07 | Amgen Inc. | Stabilization of fc-containing polypeptides |
KR102376451B1 (ko) | 2013-07-31 | 2022-03-23 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 작제물 |
EP3174894B1 (en) | 2014-07-30 | 2021-06-23 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EP3212226B1 (en) | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2015
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 US US14/811,578 patent/US9834586B2/en active Active
- 2015-07-28 ES ES15827485T patent/ES2883158T3/es active Active
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en active Application Filing
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 CR CR20170027A patent/CR20170027A/es unknown
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/ko unknown
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/zh active Active
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/es unknown
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 MX MX2017000964A patent/MX370115B/es active IP Right Grant
- 2015-07-28 UA UAA201700670A patent/UA123432C2/uk unknown
- 2015-07-28 BR BR112017001789-0A patent/BR112017001789A2/pt active Search and Examination
- 2015-07-28 TW TW104124401A patent/TWI710570B/zh active
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/ja active Active
- 2015-07-28 EA EA201692477A patent/EA035581B1/ru unknown
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/ro not_active Application Discontinuation
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en active Active
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153A1/en unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/es unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/es unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/es unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/es unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/es unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000025A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
GT201700072A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
EA201790737A1 (ru) | Комбинированная терапия | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
TWD170335S (zh) | 錶 | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
TWD170340S (zh) | 手錶 | |
EA201991997A1 (ru) | Комбинированная терапия | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
ZA202002779B (en) | Dantrolene prodrugs and methods of their use | |
PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
CO2020008319A2 (es) | Métodos para tratar la enfermedad de gaucher | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
AR103227A1 (es) | Anticuerpos anti-csf1r para el tratamiento de svp | |
EA201691907A1 (ru) | Комбинированная терапия кураксинами |